Thiagasorupan Pathma, Barreau Emmanuel, Gendron Gaël, Frau Eric, Cauquil Cécile, Adams David, Labetoulle Marc, Rousseau Antoine
Department of Ophthalmology, Bicêtre Hospital, Assistance Publique - Hôpitaux de Paris, Paris-Saclay University, French Reference Center for Hereditary Transthyretin Amyloidosis (NNERF), French Reference Network for Rare Ophthalmic diseases (OPHTARA), Le Kremlin-Bicêtre, France.
Department of Ophthalmology, Centre Hospitalier National Ophtalmologique des XV-XX, Paris, France.
Eur J Ophthalmol. 2021 Mar 29:11206721211006569. doi: 10.1177/11206721211006569.
Vitrectomy may improve visual acuity of hereditary transthyretin amyloidosis (ATTRv) patients presenting with vitreous opacities but is associated with severe complications. The objective of this study is to report visual outcomes, early and late complications of a series of ATTRv patients who underwent vitrectomy in the French ATTRv reference center.
This retrospective, single-center study, included all ATTRv patients who underwent vitrectomy between 2002 and 2017. Data were collected on pre and postoperative best corrected visual acuity (BCVA) and early and late postoperative complications.
A total of 21 eyes from 15 patients were included. The mean postoperative follow-up was 40 ± 20 months (6-160 months). BCVA increased from 0.7 ± 0.4 LogMAR preoperatively to 0.3 ± 0.4 LogMAR ( = 0.003) at last postoperative visit. During follow-up, all initially glaucomatous eyes worsened, with three eyes (37%) requiring filtering surgery and two eyes (25%) had further vision loss. Among non-glaucomatous patients, four eyes (31%) developed glaucoma with two requiring trabeculectomy and one eye (8%) had further vision loss. Three eyes (three patients) presented with complications of amyloid angiopathy. Three eyes (three patients) experienced recurrence of vitreous deposits requiring surgical revision.
Due to the potential complications, vitrectomy in ATTRv requires specific perioperative management and life-long postoperative monitoring.
玻璃体切除术可改善患有玻璃体混浊的遗传性转甲状腺素蛋白淀粉样变性(ATTRv)患者的视力,但会伴有严重并发症。本研究的目的是报告在法国ATTRv参考中心接受玻璃体切除术的一系列ATTRv患者的视力结果、早期和晚期并发症。
这项回顾性单中心研究纳入了2002年至2017年间接受玻璃体切除术的所有ATTRv患者。收集术前和术后最佳矫正视力(BCVA)以及术后早期和晚期并发症的数据。
共纳入15例患者的21只眼。术后平均随访时间为40±20个月(6 - 160个月)。末次随访时,BCVA从术前的0.7±0.4 LogMAR提高到0.3±0.4 LogMAR(P = 0.003)。随访期间,所有最初患有青光眼的眼睛病情均恶化,3只眼(37%)需要进行滤过手术,2只眼(25%)视力进一步下降。在非青光眼患者中,4只眼(31%)发生青光眼,2只眼需要小梁切除术,1只眼(8%)视力进一步下降。3只眼(3例患者)出现淀粉样血管病并发症。3只眼(3例患者)玻璃体沉积物复发需要手术修复。
由于存在潜在并发症,ATTRv患者的玻璃体切除术需要特定的围手术期管理和终身术后监测。